MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden by Andrén, O et al.
MUC-1 gene is associated with prostate cancer death: a 20-year
follow-up of a population-based study in Sweden
O Andre ´n*,1, K Fall
2, S-O Andersson
1, MA Rubin
3, TA Bismar
3, M Karlsson
4, J-E Johansson
1 and LA Mucci
5,6
1Department of Urology, O ¨rebro University Hospital, O ¨rebro 701 85, Sweden;
2Department of Medical Epidemiology and Biostatistics, Karolinska
Institutet, Stockholm 171 77, Sweden;
3Department of Pathology, Brigham and Womens Hospital, Boston, MA 02215, USA;
4Department of Pathology,
O ¨rebro University Hospital, O ¨rebro 701 85, Sweden;
5Department of Medicine, Channing Laboratory, Harvard Medical School/Brigham and Women’s
Hospital, Boston, MA 02215, USA;
6Department of Epidemiology, Harvard School of Public Health, Boston, MA 02215, USA
Anti-adhesion mucins have proven to play an important part in the biology of several types of cancer. Therefore, we test the
hypothesis that altered expression of MUC-1 is associated with prostate cancer progression. We retrieved archival tumour tissue
from a population-based cohort of 195 men with localised prostate cancer (T1a-b, Nx, M0) that has been followed for up to 20 years
with watchful waiting. Semi-automated, quantitative immunohistochemistry was undertaken to evaluate MUC-1 expression. We
modelled prostate cancer-specific death as a function of MUC-1 levels accounting for age, Gleason grade and tumour extent, and
calculated age-adjusted and multivariate adjusted hazard ratios (HR). Men that had tumours with an MUC-intensity lower or higher
than normal tissue had a higher risk of dying in prostate cancer, independent of tumour extent and Gleason score (HR 5.1 and 4.5,
respectively). Adjustment for Gleason grade and tumour stage did not alter the results. Men with a Gleason score X7 and MUC-1
deviating from the normal had a 17 (RR¼17.1 95% confidence interval¼2.3–128) times higher risk to die in prostate cancer
compared with men with Gleason score o7 and normal MUC-1 intensity. In summary, our data show that MUC-1 is an independent
prognostic marker for prostate cancer death.
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Cancer metastasis involves the dysregulation of a complex
interplay of multiple pathways. One critical step towards meta-
static potential involves the detachment of tumour cells from the
surrounding environment. Anti-adhesion molecules inhibit the
cell–cell and cell–extra-cellular matrix interactions, and may
promote development of metastatic disease by down regulating
cellular adhesion.
The mucin family of anti-adhesion molecules have been
implicated in the biological behaviour and progression of several
types of cancer (Bresalier et al, 1991; Gendler and Spicer, 1995).
The mucin MUC-1, which is expressed at the apical cell surface of
many normal secretory epithelial cells (Ho et al, 1993), contains an
extra-cellular domain that extends above most other cell
membrane-associated proteins (Hilkens et al, 1992; Hilkens et al,
1995). As such, MUC-1 has been suggested to prevent adhesion and
to promote development of metastatic disease. In prostate cancer,
overexpression of MUC-1 in tissue has been correlated both with
higher Gleason grade and advanced tumour stage (Kirschenbaum
et al, 1999). One study has, furthermore, suggested that MUC-1
expression may predict prostate cancer recurrence after prosta-
tectomy (Lapointe et al, 2004), although these results have been
challenged by others (O’Connor et al, 2005; Zellweger et al, 2005).
The disparate findings may in part be explained by the use of PSA-
recurrence as a measure of outcome, as biochemical failure does
not necessarily herald prostate cancer death (Jhaveri et al, 1999).
In the present study, we test the hypothesis that altered tumour
expression of MUC-1 is associated with prostate cancer death. We
nest the study in a population-based cohort of men with localised
prostate cancer who have been followed prospectively for more
than 20 years.
MATERIALS AND METHODS
The study population is a cohort of all cases of early prostate
cancer (T1a-b, Nx, M0) diagnosed at the O ¨rebro University
Hospital, Sweden between 1977 and 1991 by transurethral
resection of the prostate or transvesical adenoma enucleation for
symptomatic benign prostatic hyperplasia (Andren et al, 2006). As
no private institutional care was available in the region at the time
and as the population was required to seek care within their county
of residence, the cohort can be considered population-based.
Baseline evaluation at diagnosis included physical examination,
chest radiography, bone scan and skeletal radiography (if needed).
Nodal staging was not carried out. In accordance with standard
practice at that time in O ¨rebro, these patients were initially
followed expectantly (‘watchful waiting’) (Johansson et al, 2004).
Patients received clinical exams, laboratory tests and bone scans
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severy 6 months during the first 2 years after diagnosis and
subsequently at 12-month intervals. Patients that developed
metastases, as judged by bone scan, were treated with androgen
deprivation therapy if they exhibited symptoms.
Cause of death in the cohort was determined by review of
medical records by the study investigators. An autopsy was
performed if the cause of death was not clear. A validation study
regarding cause of death compared with the Swedish Death
Register showed greater than 90% concordance, with no systematic
under- or over-reporting of any cause of death. Follow-up of the
cohort with respect to mortality was 100%, and no patients were
lost to follow up.
We retrieved archival tissue specimens (formalin-fixed paraffin
embedded) and H&E slides from all 240 cases in the cohort, and we
had sufficient tumour tissue available for a total of 195 cases.
Histological examination was performed by one pathologist
(MAR) for Gleason grade who also assessed tumour extent by
calculating the ratio of the number of chips with cancer and the
total number of chips (Humphrey and Vollmer, 1988). High-
density tissue micro arrays (TMAs) were assembled from the TUR-
P specimens using the manual tissue arrayer (Beecher Instrument,
Silver Spring, MD, USA) as described previously (Perrone et al,
2000). Two representative cores were taken from each tumour
specimen. Benign tissue was also included on the TMA. After
construction, a 4mm section was cut and stained with standard
biotin–avidin complex immunohistochemistry antibodies (Mucin
1(VU4H5): sc 73–13) to evaluate MUC-1. Semi-automated,
quantitative immunohistochemistry was undertaken using the
Chromavision system, and protein intensity was measured on a
scale from 0 to 255 (Figure 1A–D).
Through March 2003, with up to 23 years of follow-up
(mean¼9, median¼8), 37 (19.0%) patients in this cohort had
died of prostate cancer. The remaining patients were considered
censored having either died of other causes (132 or 67.7%) or were
still alive without disease at time of last follow-up (26 or 13.8%).
We estimated person-time in the cohort as time between date of
diagnosis to cancer death, or censored at death from other cause or
end of follow-up (October 2003). We used Cox regression to model
time to prostate cancer death as a function of MUC-1 levels
accounting for age, Gleason grade and tumour extent. For each
individual, we calculated the mean intensity across the two cores.
We defined normal MUC-1 intensity as the mean intensity in
benign prostate tissue70.25 standard deviations (s.d.). Individuals
whose MUC-1 tumour expression was within the normal range
represented the reference group. Individuals whose tumour
expression was above or below normal were so classified. Using
Cox-regression, we calculated age-adjusted and multivariate
adjusted hazard ratios (HR). We tested for linear trend for
continuous variables using the McPhearson’s test. Furthermore, we
calculated the sensitivity and specificity of MUC-1 protein
expression as a predictor of prostate cancer death to explore its
usefulness as a biomarker of prostate cancer outcomes.
RESULTS
The baseline characteristics of the 195 patients are presented in
Table 1. Mean MUC-1 expression for all 195 patients was 107.3
(range 95–179, s.d. 10.2). Of the 43 patients that had an MUC-1
intensity close to normal tissue (Figures 1 and 2) (102.5–106),
Figure 1 Tissue micro array analysis of MUC-1 immunohistochemistry: selected images of TMA cores representing normal, high and low MUC-1 intensity
(A, B). Normal MUC-1 intensity (C, D). High (C) and Low (D) MUC-1 intensity.
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sthree (7%) died of prostate cancer, compared with 34 (23%) of the
152 patients that deviated from the normal MUC-1 intensity
(Figure 2 and 3). As illustrated in Table 2, there was no correlation
between Gleason score and MUC-1 intensity (P-value 0.8), whereas
there was a tendency to correlation between tumour extent and
MUC-1 (P-value 0.08).
The age-adjusted risk of dying of prostate cancer with respect to
MUC-1, Gleason score and tumour extent is presented in Table 3.
The risk of dying of prostate cancer was four times higher among
those with a higher (3.9 (95% confidence interval (CI)¼1.1–14))
or lower (3.8 (95%CI¼1.1–13)) MUC-1 expression than among
those with an MUC-1 expression within the normal range. After
adjusting for tumour extent and Gleason score, the effect of
MUC-1 was even stronger (HR 5.1 (95%CI¼1.4–18) and 4.5
(95%CI¼1.3–15), respectively), indicating that MUC-1 predicts
prostate cancer death independently of clinical parameters.
Table 1 Characteristics of 195 patients with incidental prostate cancer (T1a-b, Nx, M0) who received no initial treatment, according to age, Gleason
score, tumour extent and MUC-1 expression at time of diagnosis 1977–1991
N
Prostate cancer
deaths
Deaths by other
causes Alive
Mean survival
(month)
Minimum
survival (month)
Maximum
survival (month)
Age
o70 56 13 27 16 138 16 280
470 139 24 105 10 90 1 272
Gleason score
4 3 — 1 2 132 56 167
5 7 3 3 1 122 5 235
6 107 10 77 20 118 1 284
7 53 12 38 3 96 1 230
8 22 11 11 0 73 4 229
93 1 2 0 4 9 1 7 8 5
Percentage of chips with cancer
o5% 80 6 58 16 102 1 237
6–25% 85 18 57 10 97 1 280
26–50% 13 6 7 0 85 17 153
450% 17 7 10 0 54 4 143
MUC-1
Normal 43 3 35 5 118 4 284
Low 68 16 38 14 108 1 280
High 84 18 59 7 100 1 238
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Figure 2 Survival curves of 195 patients according to high-, low- and
normal MUC-1 intensity.
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Figure 3 Survival curves of 195 patients according to combination of
Gleason score and MUC-1 intensity.
Table 2 Correlation between MUC-1 intensity expression and age,
Gleason score and tumour volume
MUC-1 intensity
Factor Normal N (%) Low N (%) High N (%) P-value
Age o70 10 (23) 25 (37) 21 (25) 0.188
Age 470 33 (77) 43 (63) 63 (75)
Gleason 4–6 25 (58) 41 (60) 51(61) 0.826
Gleason 7 13 (30) 20 (29) 20 (24)
Gleason 8–9 5 (12) 7 (10) 13(16)
Percent chips o5% 15 (35) 23 (34) 42 (50) 0.085
Percent chips 5–25% 23 (54) 33 (49) 29 (35)
Percent chips 25–50% 0 (0) 5 (7) 8 (10)
Percent chips 450% 5 (12) 7 (10) 5 (6)
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sWe further cross-classified participants on MUC-1 and Gleason
score. The group with Gleason score X7 and MUC-1 lower or
higher than normal had a 17 (HR¼17.1 (95%CI¼2.3–128)) times
higher risk of prostate cancer death compared with tumours with
Gleason score o7 and normal MUC-1 intensity (Table 4).
We further assessed the ability of MUC-1 expression (deviating
from the normal range) to correctly classify prostate cancer
cases as indolent or lethal (defined as progressing to metastases
and/or death). The sensitivity for MUC-1 as predictor of
lethal prostate cancer was 0.91, whereas the specificity was
0.25 (Table 5). When combined with information on Gleason
score, the specificity increased to 0.75 but the sensitivity decreased
to 0.56.
DISCUSSION
In this population-based cohort of men with localised prostate
cancer cases (T1a-b, Nx, M0), we found that MUC-1 expression at
diagnosis was a predictor of prostate cancer death. Individuals
with dysregulated (either over or under) MUC-1 expression had a
four- to five-fold increased risk of dying of prostate cancer,
independent of clinical parameters. We further examined the
accuracy of using MUC-1 as a test for prostate cancer progression
and found that using MUC-1 alone resulted in a reasonable
sensitivity but poor specificity. The addition of information on
Gleason Score improved the specificity of the MUC-1 biomarker,
but at the cost of a lower sensitivity. Still, these data suggest that
MUC-1 may be promising to include in a panel of molecular
markers to distinguish aggressive disease from indolent at
diagnosis.
These data are in line with the accumulating evidence of the role
of MUC-1 in the cell–cell interaction. On the one hand,
overexpression of MUC-1 has been shown to increase the
metastatic potential of the cancer cells (Evangelou et al, 2002;
Schut et al, 2003; Huang et al, 2004). On the other, Kontani et al
(2001) suggested that the loss of MUC-1 expression or modulation
of its antigenicity might cause cancer cells to be unresponsive to
the effect of cytotoxic T lymphocytes. These competing mechan-
isms provide possible explanations for our findings that both over-
and underexpressions of MUC-1 increases the risk of prostate
cancer progression.
In this study, we could not confirm the findings of
Kirschenbaum et al (1999) of a correlation between MUC-1
expression and tumour differentiation. Differences in the assess-
ment of MUC-1 expression may explain the diverging results
however; although we evaluated staining intensity, Kirchenbaum
et al examined staining patterns (apical and diffuse). Our data
furthermore confirm the results of Lapointe et al (2004)
demonstrating that MUC-1 is an independent prognostic marker
that adds prognostic information over and above known risk
factors of grade and stage.
The strengths of the study include the long-term and complete
follow-up of more than 20 years. A unique feature is that the
cohort includes a sizeable number of prostate cancer deaths, which
allowed for us to evaluate an important clinical outcome. The fact
that the cases had not received any curative treatment further
enabled us to explore the effect of dysregulated MUC-1 expression
in the natural course of the disease. We employed high-density
TMAs, which represent an efficient approach for immuno-
histochemical analysis, that also reduce potential batch-to-batch
variation in staining. Moreover, the Chromavision system
provided an automated assessment of protein intensity on a
continuous scale. Our cases were diagnosed before introduction of
PSA screening in the population, and thus PSA levels at diagnosis
were not available. Although controlling PSA levels could attenuate
the association between MUC-1 and prostate cancer death, it is
unlikely that it would fully explain the relationship.
In summary, these data show that MUC-1 is an independent
prognostic marker for prostate cancer death. Furthermore,
although based on small numbers, our data suggest that MUC-1
expression together with Gleason grade provide substantial
information to distinguish prostate cancer outcomes.
As the accuracy of MUC-1 alone or together with the Gleason
Score in predicting prostate cancer progression was low, we
conclude that its use as a single biomarker in clinical decision
making is limited. Yet, we believe that alterations in MUC-1
expression may be useful as part of a composite set of biomarkers
in accurately predicting prostate cancer outcome.
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Table 3 HR and 95% CI for prostate cancer death in relation to protein
expression of MUC-1 in tumour tissue from patients with localised prostate
cancer
N
a
Prostate cancer
deaths
Crude HR
(95%CI)
HR
b
(95%CI)
MUC-1 (intensity)
Normal (102.5–
106)
43 3 1.0 1.0
Low (o102.5) 68 16 3.9 (1.1–4) 5.1 (1.4–18)
High (4105.5) 84 18 3.8 (1.1–13) 4.5 (1.3–15)
CI¼confidence interval; HR¼hazard ratio.
aA total of 195 patients were assayed for
MUC-1.
bAdjusted for age, Gleason score and tumour extent.
Table 4 Hazard ratio (95% CI) of prostate cancer death associated with
MUC-intensity and Gleason score, cross classified
Normal MUC-intensity Aberrant MUC-intensity
PC death/total N HR
(95%CI)
PC death/total N HR
(95%CI)
Gleason o7 1/25 Ref. 12/92 3.8 (0.5–29)
Gleason X7 2/18 3.8(0.3–43) 22/60 17.1 (2.3–28)
Table 5 Sensitivity, specificity, PPV and NPV of Gleason grade and
MUC-1 intensity in predicting prostate cancer death
Gleason score and
MUC-1 intensity Sensitivity Specificity PPV NPV
Aberrant MUC-1
intensity
0.91 0.25 0.22 0.93
Gleason 46 and
aberrant MUC-1
intensity
0.59 0.76 0.37 0.89
NPV¼negative predictive value; PPV¼positive predictive value.
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